Firefly Neuroscience (NASDAQ:AIFF) Posts Quarterly Earnings Results

Firefly Neuroscience (NASDAQ:AIFF) announced its quarterly earnings data on Tuesday. The company reported ($0.07) EPS for the quarter, FiscalAI reports. Firefly Neuroscience had a negative net margin of 386.15% and a negative return on equity of 77.55%. The firm had revenue of $0.65 million for the quarter.

Firefly Neuroscience Price Performance

NASDAQ AIFF traded down $0.05 on Thursday, reaching $0.99. The company had a trading volume of 3,528 shares, compared to its average volume of 3,847,973. The firm has a market cap of $15.60 million, a price-to-earnings ratio of -2.16 and a beta of 0.49. Firefly Neuroscience has a fifty-two week low of $0.62 and a fifty-two week high of $3.15. The business has a 50 day moving average of $1.14 and a two-hundred day moving average of $1.35.

Institutional Investors Weigh In On Firefly Neuroscience

An institutional investor recently bought a new position in Firefly Neuroscience stock. BlackRock Inc. bought a new stake in Firefly Neuroscience, Inc. (NASDAQ:AIFF) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 187,168 shares of the company’s stock, valued at approximately $226,000. BlackRock Inc. owned about 1.20% of Firefly Neuroscience at the end of the most recent reporting period. 4.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Wall Street Zen lowered Firefly Neuroscience from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Firefly Neuroscience in a report on Friday, August 14th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

About Firefly Neuroscience

Firefly Neuroscience, Inc. is a digital health and neuroscience company focused on using artificial intelligence to support the assessment and treatment of brain disorders. The company develops technology designed to analyze electroencephalography (EEG) data and identify patterns associated with cognitive and psychiatric conditions. Its principal platform, Brain Network Analytics (BNA), is intended to convert EEG recordings into clinically relevant measures of brain function. Firefly’s technology is designed to help healthcare professionals evaluate conditions such as Alzheimer’s disease and major depressive disorder, monitor changes in patients’ brain activity, and support more personalized treatment decisions.